Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

University of Cambridge, Genomics England Ltd., and Illumina Collaborate

Published: Monday, October 21, 2013
Last Updated: Monday, October 21, 2013
Bookmark and Share
Project will lay foundation for genomic medicine initiative will sequence 10,000 whole genomes of people with rare genetic diseases.

University of Cambridge, Genomics England Ltd., and Illumina, Inc. have announced the start of a three-year project that will sequence 10,000 whole genomes of children and adults with rare genetic diseases.

The project represents a pilot for Genomics England Ltd., which will provide 2,000 samples, and marks the beginning of the national endeavor to sequence 100,000 genomes in the UK National Health Service (NHS), announced recently by the Prime Minister, David Cameron.

“This project will bring enormous improvements to the care of patients with rare genetic diseases. It will shorten the gap between the first signs of ill-health in a person and providing a conclusive diagnosis by using the power of modern DNA sequencing methods,” said Dr. John Bradley, Director of the NIHR Cambridge Biomedical Research Centre, a partnership between the University of Cambridge and Cambridge University Hospitals.

Today, most patients with a rare genetic disease go through a diagnostic odyssey to find the cause. For many, the long search remains unsuccessful, which not only prevents the delivery of optimal care, but also may aggravate the condition.

To improve patient care in the UK National Health Service (NHS), the University of Cambridge will work with the team led by Dr. David Bentley, Vice President and Chief Scientist for Illumina, to develop the workflow and processes to bring routine clinical whole genome sequencing to the bedside.

Illumina will deliver whole genome sequence data for the project using market-leading technology invented in Cambridge. “In 1997 sequencing a person’s entire genome as part of healthcare was just an idea and it has always been my hope that one day it would turn into reality and benefit thousands of patients,” said Shankar Balasubramanian, Professor of Chemistry at Cambridge University and inventor of the sequencing by synthesis technique that is used by Illumina’s instruments to read the DNA code.

“We are excited to be partnering in this ground-breaking project to discover the genes underlying rare genetic diseases, which may lead to offering new tests and pave the way for new opportunities for treatment,” said Professor Mark Caulfield, Genomics England's Chief Scientist.

There are an estimated 7,000 rare diseases and about 3.5 million people in the UK will be affected by a rare disease at some point in their life.

“I am confident that the pioneering medical research by doctors, nurses, and scientists across the UK will receive broad support from the rare diseases community,” said Alastair Kent from Rare Diseases UK.

Sarah-Jane Marsh, Chief Executive at Birmingham Children’s Hospital, added, "More than 5 percent of babies are born with a genetic disease. At the moment, too many of the affected families are unable to access the best diagnostics and treatment available.”

The Rare Diseases Genomes Project will help to address this gap, and make the NHS a world leader in rare disease care. The cumulative knowledge which will be gained from collecting this data will improve treatment for many patients in the NHS and across the world.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Accelerator Welcomes First International Fellow
Illumina Accelerator has expanded their startup pool with the Center of Individualized Diagnostics (CID).
Wednesday, August 24, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Bio-Rad, Illumina Partner
Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.
Tuesday, January 12, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq™
A revolutionary next-generation sequencing service for epidemiological monitoring of bacterial infections.
Tuesday, December 15, 2015
Illumina Accelerator Announces Third Funding Cycle of Genomics Startups
Invests in synthetic biology, reproductive health, skin microbiome and nutrition startups.
Thursday, December 10, 2015
Desktop Genetics Receives Strategic Investment from Illumina
Illumina invests in Desktop Genetics' technology to support the platform's integration with NGS pipelines and improve CRISPR genome editing workflows.
Thursday, December 10, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Illumina Completes Acquisition of GenoLogics
Illumina’s to drive the adoption of sequencing in new markets and improve the genomic workflow.
Wednesday, September 02, 2015
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Leukaemia Cell Movement Gives Clues to Tackling Treatment-Resistant Disease
Researchers at Imperial College London have suggested that the act of moving itself may help the cells to survive, possibly through short-lived interactions with an array of our own cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos